1. Routine TB surveillance indicators
1.1. People diagnosed with TB disease
1.1.1 Number of people diagnosed with a new episode of TB
1.1.2 People diagnosed with a new episode of TB per 100 000 population
1.1.3 Number of people re-registered for TB treatment
1.1.4 Percentage of people diagnosed with a new episode of pulmonary TB whose disease was bacteriologically confirmed
1.1.5 Number of people diagnosed with bacteriologically confirmed pulmonary TB that is resistant to rifampicin
1.1.6 Percentage of people diagnosed with a new episode of TB whose HIV status was documented
1.1.7 Percentage of people with a new episode of TB who are HIV-positive, among those with documented HIV status
1.1.8 Percentage of people living with HIV diagnosed with a new episode of TB who were on or newly enrolled on antiretroviral therapy
1.2. Coverage of testing for drug resistance among people with bacteriologically confirmed pulmonary TB
1.2.1 Percentage of people diagnosed with a new episode of TB who were initially tested with a WRD
1.2.2 Percentage of people diagnosed with bacteriologically confirmed pulmonary TB tested for rifampicin susceptibility
1.2.3 Percentage of people diagnosed with bacteriologically confirmed pulmonary TB who were tested for susceptibility to both rifampicin and isoniazid
1.2.4 Percentage of people with documented test results for susceptibility to rifampicin who were tested for susceptibility to isoniazid
1.2.5 Percentage of people with rifampicin-resistant pulmonary TB who were tested for susceptibility to fluoroquinolones
1.2.6 Percentage of people with pulmonary TB resistant to both rifampicin and fluoroquinolones (pre-XDR-TB) who were tested for susceptibility to bedaquiline and linezolid
1.2.7 Percentage of people with bacteriologically confirmed pulmonary TB resistant to both rifampicin and fluoroquinolones (pre-XDR-TB) who were tested for susceptibility to bedaquiline
1.2.8 Percentage of people with bacteriologically confirmed pulmonary TB resistant to both rifampicin and fluoroquinolones (pre-XDR-TB) who were tested for susceptibility to linezolid
1.3. Results from testing for drug resistance among people with bacteriologically confirmed pulmonary TB
1.3.1 Percentage of people tested for RR-TB who were resistant to rifampicin
1.3.2 Percentage of people tested for MDR-TB who had MDR-TB
1.3.3 Percentage of people tested for Hr-TB who had Hr-TB
1.3.4 Percentage of people tested for pre-XDR-TB who had pre-XDR-TB
1.3.5 Percentage of people tested for XDR-TB who had XDR-TB
1.4. People requiring treatment for TB disease
1.4.1 Percentage of people diagnosed with TB and started on TB treatment among all registered cases
1.4.2 Number of RR-TB diagnosis and enrolment into second-line TB treatment
1.4.3 Treatment outcomes of people diagnosed with a new episode of TB and treated for drug-susceptible TB
1.4.4 Treatment outcomes of people with TB/HIV patients (new episode of TB)
1.4.5 Treatment outcomes of people with RR/MDR-TB
1.5. Screening and prevention
1.5.1 Percentage of household contacts (or all close contacts) evaluated for TB
1.5.2 Number of individuals started on shorter TB preventive treatment regimens containing rifampicin or rifapentine
1.5.3 Number of household contacts (or close TB contacts) started on TB preventive treatment
1.5.4 Percentage of household contacts (or all close contacts) under 5 years who were started on TB preventive treatment out of those eligible
1.5.5 Percentage of household contacts (or all close contacts) of all ages who were started on TB preventive treatment out of those eligible
1.5.6 Percentage of household contacts (or all close contacts) who completed TB preventive treatment
1.5.7 Number of people living with HIV started on TB preventive treatment
1.5.8 Percentage of people living with HIV newly initiated on ART who were started on TB preventive treatment out of those eligible
1.5.9 Percentage of people living with HIV who completed TB preventive treatment
Metadata
Glossary and definitions
| New episode of TB | A person with TB disease who has either
|
|---|---|
| Re-registered case | A person with TB disease who has been notified previously as a TB case, who started treatment and took TB drugs for at least 1 month but who was not declared cured or treatment completed, and is now being started on a new course of TB treatment. Examples of re-registered cases include:
|
| Bacteriologically confirmed TB | A person with TB disease from whom a bacteriological specimen is positive by a WHO recommended rapid diagnostic test, culture, or smear microscopy. |
| HIV status documentation | Documentation of a person's HIV status (positive, negative, or unknown) in their medical records or relevant health information systems. |
| Antiretroviral therapy | The daily use of combination of HIV medicines to treat HIV infection. |
| Molecular WHO-recommended rapid diagnostic test (mWRD) | Diagnostic tests approved by WHO that employs molecular-based techniques for the diagnosis of TB. |
| Testing for drug susceptibility | In vitro testing of a strain of M. Tuberculosis complex using either: 1) molecular, genotypic techniques to detect resistance-conferring mutations; or 2) phenotypic methods to determine susceptibility to a medicine. |
| Rifampicin-resistant TB (RR-TB) | A person with TB disease who is infected with a strain of M. Tuberculosis complex that is resistant to rifampicin. |
| Isoniazid-resistant, rifampicin-susceptible TB (Hr-TB) | A person with TB disease who is infected with a strain of M. tuberculosis complex that is resistant to isoniazid but susceptible to rifampicin |
| Multidrug-resistant TB (MDR-TB) | A person with TB disease who is infected with a strain of M. tuberculosis complex that is resistant to both rifampicin and isoniazid. |
| MDR/RR-TB | MDR-TB is a subset of RR-TB, and the two are often grouped together using the term MDR/RR-TB. |
| Pre-extensively drug-resistant TB (pre-XDR-TB) | A person with TB disease who is infected with a strain of M. tuberculosis complex that is resistant to rifampicin (and which may also be resistant to isoniazid), and which is also resistant to at least one fluoroquinolone (either levofloxacin or moxifloxacin). |
| Extensively drug-resistant TB (XDR-TB) | A person with TB disease who is infected with a strain of M. tuberculosis complex that is resistant to rifampicin (and which may also be resistant to isoniazid) as well as resistant to at least one fluoroquinolone (levofloxacin or moxifloxacin) and at least one other “Group A” drug (bedaquiline or linezolid). |
| First-line TB medicine (or drug) | An agent used to treat a person with drug-susceptible TB disease. First-line treatment regimens comprise combination of the following drugs: isoniazid, rifampicin, ethambutol, pyrazinamide, rifabutin, rifapentine, moxifloxacin. |
| Second-line TB medicine (or drug) | An agent to treat a person with drug-resistant TB disease. Second-line treatment regimens comprise combination of the following drugs: Group A: levofloxacin or moxifloxacin, bedaquiline, linezolid. Group B: clofazimine, cycloserine or terizidone. Group C (when Group A and Group B cannot be used): ethambutol, delamanid, pyrazinamide, imipenem-cilastatin or meropenem, amikacin, ethionamide or prothionamide, p-aminosalicylic acid. |
| Cured | A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national policy with evidence of bacteriological response and no evidence of failure. In this context, a bacteriological response is defined as a bacteriological conversion with no reversion. A bacteriological conversion occurs when a patient with bacteriologically confirmed TB has at least two consecutive negative cultures (for DR-TB and DS-TB) or smears (for DS-TB only), taken on different occasions at least 7 days apart. Bacteriological reversion occurs when a patient with bacteriologically confirmed TB has at least two consecutive cultures (for DR-TB and DS-TB) or smears (for DS-TB only), taken on different occasions at least 7 days apart, which are positive either after a bacteriological conversion or in patients without bacteriological confirmation of TB. |
| Treatment completed | A person with TB disease who completed treatment as recommended by the national policy whose outcome does not meet the definition for cure or treatment failure. |
| Treatment success | A person with TB disease who is either cured or completes their treatment. |
| Treatment failed | A person with TB disease whose treatment regimen needed to be terminated or permanently changed to a new regimen option or treatment strategy. Reasons for regimen change may include no clinical response and/or no bacteriological response, an adverse drug reaction or evidence of additional drug resistance to medicines in the regimen. |
| Died | A person with TB disease who died for any reason before starting, or during the course of, treatment. |
| Lost to follow-up | A person with TB disease whose treatment was interrupted for two consecutive months or more (for both case and treatment outcomes). |
| Not evaluated | A person with TB disease to whom no treatment outcome was assigned, excluding those lost to follow-up. |
| Household contact | A person who has shared the same enclosed living space as the index case for one or more nights or for frequent or extended daytime periods in the 3 months before TB disease was identified in the index case. |
| Preventive TB treatment | Treatment offered to individuals who are considered at risk of progression from TB infection to TB disease. Also referred to as treatment of TB infection, treatment for latent TB infection or TB preventive therapy. |
Copyright and licensing
| Copyright | Attribution 4.0 International (CC BY 4.0) |
|---|---|
| License | The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies. Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you. You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion. Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition: Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final. |
| Permission type | Publicly accessible |
| Prohibited uses | You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content. You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services. |
| Citation | World Health Organization 2025 data.who.int, WHO TB dashboard [Dashboard]. https://data.who.int/dashboards/tuberculosis/ |
| Disclaimer | WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you. Maps All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use. For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions. |